314 related articles for article (PubMed ID: 19728784)
1. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States.
Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS
Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784
[TBL] [Abstract][Full Text] [Related]
2. Ethical reflections on clinical trials with human tissue engineered products.
Trommelmans L; Selling J; Dierickx K
J Med Ethics; 2008 Sep; 34(9):e1. PubMed ID: 18757609
[TBL] [Abstract][Full Text] [Related]
3. [Industrialization of regenerative medicine in Japan].
Sugawara K; Hata K
Clin Calcium; 2008 Dec; 18(12):1751-6. PubMed ID: 19043189
[TBL] [Abstract][Full Text] [Related]
4. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics.
Smith DS
Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924
[No Abstract] [Full Text] [Related]
5. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU.
Brévignon-Dodin L
Biomed Mater Eng; 2010; 20(3):121-6. PubMed ID: 20930319
[TBL] [Abstract][Full Text] [Related]
6. Great expectations: private sector activity in tissue engineering, regenerative medicine, and stem cell therapeutics.
Lysaght MJ; Jaklenec A; Deweerd E
Tissue Eng Part A; 2008 Feb; 14(2):305-15. PubMed ID: 18333783
[TBL] [Abstract][Full Text] [Related]
7. US FDA outreach to the regenerative medicine community: challenges and opportunities.
Whittlesey KJ; Witten C
Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
[TBL] [Abstract][Full Text] [Related]
8. Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.
Witten CM; McFarland RD; Simek SL
Stem Cells Transl Med; 2015 Dec; 4(12):1495-9. PubMed ID: 26494784
[TBL] [Abstract][Full Text] [Related]
9. The role of the FDA in the effort against AIDS.
Young FE
Public Health Rep; 1988; 103(3):242-5. PubMed ID: 3131814
[TBL] [Abstract][Full Text] [Related]
10. Commercial development of cell-based therapeutics: strategic considerations along the drug to tissue spectrum.
Parenteau NL
Regen Med; 2009 Jul; 4(4):601-11. PubMed ID: 19580408
[TBL] [Abstract][Full Text] [Related]
11. Tissue engineering and regenerative medicine: manufacturing challenges.
Williams DJ; Sebastine IM
IEE Proc Nanobiotechnol; 2005 Dec; 152(6):207-10. PubMed ID: 16441181
[TBL] [Abstract][Full Text] [Related]
12. The long journey from stem cells to medical product.
Parson A
Cell; 2006 Apr; 125(1):9-11. PubMed ID: 16615881
[TBL] [Abstract][Full Text] [Related]
13. Regenerative medicine: a primer for paediatricians.
Polak DJ
Early Hum Dev; 2009 Nov; 85(11):685-9. PubMed ID: 19783108
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Regenerative Medicine Products.
Gee AP
Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
[TBL] [Abstract][Full Text] [Related]
15. FDA regulation of stem cell-based products.
Fink DW
Science; 2009 Jun; 324(5935):1662-3. PubMed ID: 19556496
[TBL] [Abstract][Full Text] [Related]
16. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
von Tigerstrom B
Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
[TBL] [Abstract][Full Text] [Related]
17. Awareness of the role of science in the FDA regulatory submission process: a survey of the TERMIS-Americas membership.
Johnson PC; Bertram TA; Carty NR; Hellman KB; Tawil BJ; Van Dyke M
Tissue Eng Part A; 2014 Jun; 20(11-12):1565-82. PubMed ID: 24665855
[TBL] [Abstract][Full Text] [Related]
18. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
[TBL] [Abstract][Full Text] [Related]
19. [Supervision, administration and standard research related to tissue engineered medical products].
Xi TF; Chen L; Zhao P
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 Nov; 17(6):480-7. PubMed ID: 14663949
[TBL] [Abstract][Full Text] [Related]
20. FDA perspective on specifications for biotechnology products--from IND to PLA.
Murano G
Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
